Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of cenerimod added to background therapy for active lupus nephritis
CTR20261782Phase 3Active
- Sponsor
- Viatris
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cenerimod in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by Viatris. Started Feb 2026; status: active.
02
Drugs
cenerimod
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261782.